Farxiga (dapagliflozin) Letter of Medical Necessity
Farxiga (dapagliflozin) prior authorization may require documentation of indication and prior step therapy through preferred SGLT2 inhibitors like empagliflozin.
FDA-Approved Indications
- ● type 2 diabetes mellitus
- ● heart failure (HFrEF and HFpEF)
- ● chronic kidney disease
Why Farxiga Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Step therapy: Jardiance preferred
- 2. Indication not specified
- 3. Renal function missing
What to Include in a Farxiga Letter of Medical Necessity
Document the indication (T2DM, HFrEF, HFpEF, CKD), labs supporting eligibility, prior SGLT2 trials if any, and outcomes trial data (DAPA-HF, DELIVER, or DAPA-CKD) supporting use.
Key clinical evidence to cite:
- ✓ DAPA-HF
- ✓ DELIVER
- ✓ DAPA-CKD
- ✓ DECLARE-TIMI 58
Relevant guidelines:
- 📖 ADA 2024 Standards of Care
- 📖 ACC/AHA HF Guidelines
- 📖 KDIGO 2022 Guidelines
Farxiga Prior Authorization Criteria
Standard criteria across major US payers for Farxiga. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Step therapy: Jardiance preferred
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Farxiga
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Farxiga Prior Authorization FAQ
Why was my Farxiga prior authorization denied?
The most common denial reasons for Farxiga are: Step therapy: Jardiance preferred; Indication not specified; Renal function missing.
What should a Farxiga Letter of Medical Necessity include?
Document the indication (T2DM, HFrEF, HFpEF, CKD), labs supporting eligibility, prior SGLT2 trials if any, and outcomes trial data (DAPA-HF, DELIVER, or DAPA-CKD) supporting use.
Which payers cover Farxiga?
Farxiga is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, Medicare Part D, though formulary tier and prior authorization criteria vary.